407 related articles for article (PubMed ID: 17622249)
1. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis.
Weichert W; Boehm M; Gekeler V; Bahra M; Langrehr J; Neuhaus P; Denkert C; Imre G; Weller C; Hofmann HP; Niesporek S; Jacob J; Dietel M; Scheidereit C; Kristiansen G
Br J Cancer; 2007 Aug; 97(4):523-30. PubMed ID: 17622249
[TBL] [Abstract][Full Text] [Related]
2. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.
Wang W; Abbruzzese JL; Evans DB; Larry L; Cleary KR; Chiao PJ
Clin Cancer Res; 1999 Jan; 5(1):119-27. PubMed ID: 9918209
[TBL] [Abstract][Full Text] [Related]
3. [Expression of heparanase and nuclear factor kappa B in pancreatic adenocarcinoma].
Wu WJ; Pan CE; Liu QG; Meng KW; Yu HB; Wang YL; Zhao L
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Aug; 27(8):1267-70. PubMed ID: 17715045
[TBL] [Abstract][Full Text] [Related]
4. Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer.
Nakashima H; Nakamura M; Yamaguchi H; Yamanaka N; Akiyoshi T; Koga K; Yamaguchi K; Tsuneyoshi M; Tanaka M; Katano M
Cancer Res; 2006 Jul; 66(14):7041-9. PubMed ID: 16849549
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase Cdelta activates RelA/p65 and nuclear factor-kappaB signaling in response to tumor necrosis factor-alpha.
Lu ZG; Liu H; Yamaguchi T; Miki Y; Yoshida K
Cancer Res; 2009 Jul; 69(14):5927-35. PubMed ID: 19549902
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50/p105, p52/p100 and RelA in prostate cancers.
Seo SI; Song SY; Kang MR; Kim MS; Oh JE; Kim YR; Lee JY; Yoo NJ; Lee SH
APMIS; 2009 Aug; 117(8):623-8. PubMed ID: 19664134
[TBL] [Abstract][Full Text] [Related]
7. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients.
Montagut C; Tusquets I; Ferrer B; Corominas JM; Bellosillo B; Campas C; Suarez M; Fabregat X; Campo E; Gascon P; Serrano S; Fernandez PL; Rovira A; Albanell J
Endocr Relat Cancer; 2006 Jun; 13(2):607-16. PubMed ID: 16728586
[TBL] [Abstract][Full Text] [Related]
8. Activation of the NF-kappaB signalling pathway in diffuse large B-cell lymphoma: clinical implications.
Espinosa I; Briones J; Bordes R; Brunet S; Martino R; Sureda A; Sierra J; Prat J
Histopathology; 2008 Oct; 53(4):441-9. PubMed ID: 18983609
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of nuclear factor κ B expression in patients with advanced cervical cancer undergoing radiation therapy followed by hysterectomy.
Baiocchi G; Begnami MD; Fukazawa EM; Oliveira RA; Faloppa CC; Kumagai LY; Badiglian-Filho L; Pellizzon AC; Maia MA; Jacinto AA; Soares FA; Lopes A
J Clin Pathol; 2012 Jul; 65(7):614-8. PubMed ID: 22447917
[TBL] [Abstract][Full Text] [Related]
10. Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer.
Zhang D; Jin X; Wang F; Wang S; Deng C; Gao Z; Guo C
Ann Surg Oncol; 2007 Dec; 14(12):3581-92. PubMed ID: 17899287
[TBL] [Abstract][Full Text] [Related]
11. Co-expression of NF-κB-p65 and phosphorylated NF-κB-p105 is associated with poor prognosis in surgically resectable non-small cell lung cancer.
Lin G; Li C; Huang C; Zhuang W; Huang Y; Xu H; Miao Q; Hu D
J Cell Mol Med; 2018 Mar; 22(3):1923-1930. PubMed ID: 29363879
[TBL] [Abstract][Full Text] [Related]
12. RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.
Zhang M; Xu-Monette ZY; Li L; Manyam GC; Visco C; Tzankov A; Wang J; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Pham LV; Young KH
Aging (Albany NY); 2016 Dec; 8(12):3321-3340. PubMed ID: 27941215
[TBL] [Abstract][Full Text] [Related]
13. Nuclear factor-kappaB p65 is a prognostic indicator in gastric carcinoma.
Yamanaka N; Sasaki N; Tasaki A; Nakashima H; Kubo M; Morisaki T; Noshiro H; Yao T; Tsuneyoshi M; Tanaka M; Katano M
Anticancer Res; 2004; 24(2C):1071-5. PubMed ID: 15154625
[TBL] [Abstract][Full Text] [Related]
14. Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer.
Guo RX; Qiao YH; Zhou Y; Li LX; Shi HR; Chen KS
Pathol Int; 2008 Dec; 58(12):749-56. PubMed ID: 19067848
[TBL] [Abstract][Full Text] [Related]
15. Pim-1 controls NF-kappaB signalling by stabilizing RelA/p65.
Nihira K; Ando Y; Yamaguchi T; Kagami Y; Miki Y; Yoshida K
Cell Death Differ; 2010 Apr; 17(4):689-98. PubMed ID: 19911008
[TBL] [Abstract][Full Text] [Related]
16. [Expression of nuclear factor-kappa-B/P65 and fragile histidine triad in colorectal carcinoma and clinical significance thereof].
Lü Y; Liu L; Zhao P
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(9):610-4. PubMed ID: 18646716
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
Wang W; Abbruzzese JL; Evans DB; Chiao PJ
Oncogene; 1999 Aug; 18(32):4554-63. PubMed ID: 10467400
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin mimics ARF tumor suppressor regulation of RelA (p65) nuclear factor-kappaB transactivation.
Campbell KJ; Witty JM; Rocha S; Perkins ND
Cancer Res; 2006 Jan; 66(2):929-35. PubMed ID: 16424027
[TBL] [Abstract][Full Text] [Related]
19. p65 controls NF-κB activity by regulating cellular localization of IκBβ.
Valovka T; Hottiger MO
Biochem J; 2011 Mar; 434(2):253-63. PubMed ID: 21158742
[TBL] [Abstract][Full Text] [Related]
20. N-tosyl-L-phenylalanine chloromethyl ketone inhibits NF-kappaB activation by blocking specific cysteine residues of IkappaB kinase beta and p65/RelA.
Ha KH; Byun MS; Choi J; Jeong J; Lee KJ; Jue DM
Biochemistry; 2009 Aug; 48(30):7271-8. PubMed ID: 19591457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]